search
for
 About Bioline  All Journals  Testimonials  Membership  News


African Journal of Biomedical Research
Ibadan Biomedical Communications Group
ISSN: 1119-5096
Vol. 10, No. 2, 2007, pp. 189-192
Bioline Code: md07025
Full paper language: English
Document type: Short Communication
Document available free of charge

African Journal of Biomedical Research, Vol. 10, No. 2, 2007, pp. 189-192

 en Interference of Infectious Bursal Diseases (IBD) Virus and Vaccine with the Immune Responses of Guinea Fowls to Newcastle Disease Lasota Vaccination
El-Yuguda, A.D.; Wachida, N. & Baba, S.S.

Abstract

The interference of Infectious bursal disease (IBD) virus and vaccine with the immune response of the grey brested guinea fowl (Numida meleagridis galeata palas) to Newcastle desease (ND) “LaSota” vaccine was studied using hemagglutination inhibition (HI) test for detection of ND virus antibody and agar gel precipitation test (AGPT) for the presence of IBD virus antibody. A statistically significant difference (p<0.05) in HI antibody response was noted between the group vaccinated with ND “LaSota” vaccine alone and those infected with IBD virus or vaccinated with IBD vaccine and later vaccinated with ND “LaSota”. The Newcastle disease “LaSota” vaccinated group showed highest Geometric Mean Titre (GMT) of HI antibody response of 80 while the IBD virus infected and IBD vaccinated group gave 32 and 19 respectively. Expectedly the IBD infected or vaccinated groups seroconverted to the IBD infection or vaccination. It is concluded that IBD virus or vaccine interfered with the immune response of the guinea fowls to ND “LaSota” vaccine.

Keywords
Infectious bursal disease, Newcastle disease LaSota vaccine, guinea fowls, immune response.

 
© Copyright 2007 - Ibadan Biomedical Communications Group

Home Faq Resources Email Bioline
© Bioline International, 1989 - 2024, Site last up-dated on 01-Sep-2022.
Site created and maintained by the Reference Center on Environmental Information, CRIA, Brazil
System hosted by the Google Cloud Platform, GCP, Brazil